Published in PLoS One on September 08, 2011
Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose | NCT01300988
Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals | NCT00428519
Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev (2014) 1.40
Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults. AIDS (2015) 1.00
Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV. J Transl Med (2016) 0.81
Involvement of substance P and the NK-1 receptor in pancreatic cancer. World J Gastroenterol (2014) 0.78
Substance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor. J Neurovirol (2013) 0.78
Substance P and Antagonists of the Neurokinin-1 Receptor in Neuroinflammation Associated with Infectious and Neurodegenerative Diseases of the Central Nervous System. J Neurol Neuromedicine (2016) 0.77
Neurokinin-1 receptor antagonists: A new revolution in antiretroviral treatment? Indian J Sex Transm Dis (2016) 0.75
Substance P and sickle cell disease-a marker for pain and novel therapeutic approaches. Br J Haematol (2016) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis (1999) 9.81
T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis (2003) 8.00
Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood (2004) 7.09
Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis (2008) 6.03
Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 5.30
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr (2007) 4.67
CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet (2006) 4.06
Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 2.83
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr (2010) 2.47
Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis (2009) 1.95
The tachykinin peptide family. Pharmacol Rev (2002) 1.82
Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry (2005) 1.67
Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes. Proc Natl Acad Sci U S A (2001) 1.36
Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos (2004) 1.24
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis (2007) 1.17
Elevated substance P levels in HIV-infected men. AIDS (2001) 1.16
Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor. Proc Natl Acad Sci U S A (2008) 1.14
Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol (2006) 1.09
Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry (2006) 1.07
HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies. Curr Neurol Neurosci Rep (2008) 1.04
Raltegravir: a new antiretroviral class for salvage therapy. Lancet (2007) 1.04
Elevated substance P levels in HIV-infected women in comparison to HIV-negative women. AIDS Res Hum Retroviruses (2008) 1.04
Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals. AIDS (2010) 1.02
Neurokinin-1 receptor antagonist (aprepitant) suppresses HIV-1 infection of microglia/macrophages. J Neuroimmune Pharmacol (2008) 0.99
Substance P inhibits natural killer cell cytotoxicity through the neurokinin-1 receptor. J Leukoc Biol (2010) 0.90
A sensitive and rapid liquid chromatography-tandem mass spectrometry method for the quantification of the novel neurokinin-1 receptor antagonist aprepitant in rhesus macaque plasma, and cerebral spinal fluid, and human plasma with application in translational NeuroAIDs research. J Pharm Biomed Anal (2008) 0.82
Novel method for determination of substance P levels in unextracted human plasma by using acidification. Clin Vaccine Immunol (2009) 0.81
Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol (2003) 5.43
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet (2010) 5.41
Shortening the timeline of pediatric phase I trials: the rolling six design. J Clin Oncol (2008) 2.46
Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry (2002) 2.26
Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS (2006) 1.99
Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis (2004) 1.98
Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS (2010) 1.87
Long-term observation of adolescents initiating HAART therapy: three-year follow-up. AIDS Res Hum Retroviruses (2007) 1.84
Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry (2002) 1.73
Mitochondrial dysfunction in peripheral blood mononuclear cells in pediatric septic shock. Pediatr Crit Care Med (2015) 1.59
Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J (2005) 1.53
Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr (2006) 1.49
Immune suppression and immune activation in depression. Brain Behav Immun (2010) 1.48
Population pharmacokinetics of pentobarbital in neonates, infants, and children after open heart surgery. J Pediatr (2011) 1.47
Differential role of protein kinase C delta isoform in agonist-induced dense granule secretion in human platelets. J Biol Chem (2003) 1.33
Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology (2005) 1.31
Real-time RT-PCR for quantitation of hepatitis C virus RNA. J Virol Methods (2002) 1.29
Neurokinin 1 receptor isoforms and the control of innate immunity. Trends Immunol (2009) 1.27
Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol (2003) 1.25
Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation. Br J Haematol (2008) 1.24
Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS (2002) 1.24
Substance P and neurokinin-1 receptor modulation of HIV. J Neuroimmunol (2004) 1.24
Messenger-specific role for nicotinic acid adenine dinucleotide phosphate in neuronal differentiation. J Biol Chem (2006) 1.23
Morphine enhances HIV infection of human blood mononuclear phagocytes through modulation of beta-chemokines and CCR5 receptor. J Investig Med (2002) 1.23
Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy. AIDS Patient Care STDS (2008) 1.22
Quantification of CCR5 mRNA in human lymphocytes and macrophages by real-time reverse transcriptase PCR assay. Clin Diagn Lab Immunol (2003) 1.21
Natural killer cells inhibit hepatitis C virus expression. J Leukoc Biol (2004) 1.21
Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J (2009) 1.20
Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J Clin Microbiol (2005) 1.19
CD8+CD38+ T cells but not HIV type 1 RNA viral load predict CD4+ T cell loss in a predominantly minority female HIV+ adolescent population. AIDS Res Hum Retroviruses (2004) 1.19
HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS (2006) 1.15
Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biol Psychiatry (2003) 1.14
Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor. Proc Natl Acad Sci U S A (2008) 1.14
Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group. Pediatr Blood Cancer (2010) 1.14
Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J (2011) 1.14
Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med (2013) 1.14
Morphine enhances HIV infection of neonatal macrophages. Pediatr Res (2003) 1.13
The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol (2009) 1.12
Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort. AIDS Res Hum Retroviruses (2006) 1.11
Alcohol potentiates hepatitis C virus replicon expression. Hepatology (2003) 1.11
Relationship of plasma HIV-1 RNA dynamics to baseline factors and virological responses to highly active antiretroviral therapy in adolescents (aged 12-22 years) infected through high-risk behavior. J Infect Dis (2004) 1.11
Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf (2009) 1.10
Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics (2013) 1.10
Association of resolution of major depression with increased natural killer cell activity among HIV-seropositive women. Am J Psychiatry (2005) 1.08
Implementing asthma guidelines using practice facilitation and local learning collaboratives: a randomized controlled trial. Ann Fam Med (2014) 1.07
Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization. J Clin Endocrinol Metab (2014) 1.06
Alcohol potentiates HIV-1 infection of human blood mononuclear phagocytes. Alcohol Clin Exp Res (2002) 1.06
Glutathione, glutathione peroxidase, and selenium status in HIV-positive and HIV-negative adolescents and young adults. Am J Clin Nutr (2007) 1.06
Immune activation and oxidative damage in HIV-positive and HIV-negative adolescents. J Acquir Immune Defic Syndr (2005) 1.06
Enhanced psychosocial well-being following participation in a mindfulness-based stress reduction program is associated with increased natural killer cell activity. J Altern Complement Med (2010) 1.05
Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis (2013) 1.05
Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr (2008) 1.04
Methadone enhances human immunodeficiency virus infection of human immune cells. J Infect Dis (2001) 1.04
Mode of delivery and postpartum morbidity in Latin American and Caribbean countries among women who are infected with human immunodeficiency virus-1: the NICHD International Site Development Initiative (NISDI) Perinatal Study. Am J Obstet Gynecol (2006) 1.04
Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. J Neuroimmune Pharmacol (2007) 1.03
Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals. AIDS (2010) 1.02
Modeling and simulation of adherence: approaches and applications in therapeutics. AAPS J (2005) 1.02
Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R). J Leukoc Biol (2008) 1.01
HIV enhances substance P expression in human immune cells. FASEB J (2002) 1.01
Depression and HIV infection: impact on immune function and disease progression. CNS Spectr (2003) 1.01
Transcriptional and epigenetic regulation of KIAA1199 gene expression in human breast cancer. PLoS One (2012) 1.00
Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndrome. Biol Psychiatry (2007) 1.00
Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults. AIDS (2015) 1.00
Neurokinin-1 receptor antagonist (aprepitant) suppresses HIV-1 infection of microglia/macrophages. J Neuroimmune Pharmacol (2008) 0.99
Association between alcohol use and HIV viral load. J Acquir Immune Defic Syndr (2011) 0.99
Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol (2008) 0.99
Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. Blood (2013) 0.99
Interaction of FGF-2 with IGF-1 and BDNF in stimulating Akt, ERK, and neuronal survival in hippocampal cultures. Brain Res (2007) 0.98
Population pharmacokinetic investigation of actinomycin-D in children and young adults. J Clin Pharmacol (2008) 0.98
Molecular mechanism of nucleotide-induced primary granule release in human neutrophils: role for the P2Y2 receptor. Am J Physiol Cell Physiol (2003) 0.98
Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or Fever. J Pediatr Pharmacol Ther (2011) 0.98
A time to keep and a time to cast away categories of tumor response. J Clin Oncol (2011) 0.97
Interleukin-1beta upregulates functional expression of neurokinin-1 receptor (NK-1R) via NF-kappaB in astrocytes. Glia (2004) 0.97
Peripheral blood lymphocyte subsets in adolescents: a longitudinal analysis from the REACH project. Clin Diagn Lab Immunol (2002) 0.97
Real-time reverse transcription-PCR quantitation of substance P receptor (NK-1R) mRNA. Clin Diagn Lab Immunol (2005) 0.97
Interleukin-1beta stimulates macrophage inflammatory protein-1alpha and -1beta expression in human neuronal cells (NT2-N). J Neurochem (2003) 0.97
Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost (2002) 0.96
Quantification of substance p mRNA in human immune cells by real-time reverse transcriptase PCR assay. Clin Diagn Lab Immunol (2002) 0.96
Naltrexone inhibits alcohol-mediated enhancement of HIV infection of T lymphocytes. J Leukoc Biol (2006) 0.95
Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinase-dependent mechanism. J Biol Chem (2009) 0.95
Alpha-defensins inhibit HIV infection of macrophages through upregulation of CC-chemokines. AIDS (2004) 0.95
Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. Anesth Analg (2010) 0.94
Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J (2006) 0.94
Assessment of thymic activity in human immunodeficiency virus-negative and -positive adolescents by real-time PCR quantitation of T-cell receptor rearrangement excision circles. Clin Diagn Lab Immunol (2003) 0.93
Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women. J Adolesc Health (2011) 0.93
Perceived stress is associated with impaired T-cell response to HPV16 in women with cervical dysplasia. Ann Behav Med (2008) 0.92
Missed opportunities for prevention of mother-to-child transmission of human immunodeficiency virus type 1 in Latin America and the Caribbean: the NISDI perinatal study. Pediatr Infect Dis J (2007) 0.92
Neurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected rhesus macaques: implications for substance P in NK1-R immune cell trafficking into the CNS. Am J Pathol (2010) 0.92
Substance P induces rapid and transient membrane blebbing in U373MG cells in a p21-activated kinase-dependent manner. PLoS One (2011) 0.91